Annual Report and Accounts and AGM Notification

RNS Number : 4505V

Oncimmune Holdings PLC

03 November 2017

 

3 November 2017

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Annual Report and Accounts and AGM Notification

Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today gives notice that copies of the Annual Report and Accounts for the year ended 31 May 2017 and the Notice of Annual General Meeting ("AGM") have been sent to shareholders.  These documents are available to view on the "Investors" section of the Company's website at http://oncimmune.com/. Oncimmune announced results for the year ended 31 May 2017 on 20 October 2017.

Further copies of the Annual Report will be available from the Company Secretary, Oncimmune, Clinical Sciences Building, Nottingham City Hospital, Hucknall Road, Nottingham

NG5 1PB.

Oncimmune also announces that its Annual General Meeting will be held on 29 November 2017. The meeting will be held at Peachey & Co LLP, 95 Aldwych, London, WC2B 4JF, commencing at 9.30 am.

-Ends-

For further information:

Oncimmune Holdings plc

Geoffrey Hamilton-Fairley, Chief Executive Officer

[e-mail]

Zeus Capital Limited (Nominated Adviser and Broker)

Giles Balleny, Hugh Kingsmill Moore

[phone]

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Matthew Neal, Lindsey Neville

[e-mail]

[phone]

About Oncimmune

Oncimmune is a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company's first product, EarlyCDT®-Lung, was launched in 2012, as a CLIA test in the USA and since then over 150,000 commercial tests have been sold. EarlyCDT®-Lung is available through physicians in the US and also privately in the UK and other regions. EarlyCDT®-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,210 high-risk smokers. EarlyCDT® tests for liver and ovarian cancer are in development.

Oncimmune is headquartered in Nottingham, United Kingdom with testing facilities in the US and joined AIM in May 2016 under the ticker ONC.L. For more information, visit www.oncimmune.com

 

END

 

 

MSCKMMGMVZLGNZM